Zimmer Biomet Trims FY23 Revenue Growth Outlook - Update
(RTTNews) - While reporting financial results for the third quarter on Tuesday, medical technology firm Zimmer Biomet Holdings Inc. (ZBH) reaffirmed its adjusted earnings outlook for the full-year 2023, while trimming annual revenue growth guidance.
For fiscal 2023, the company now projects adjusted earnings in a range of $7.47 to $7.57 per share on revenue growth of 6.0 to 6.5 percent from last year.
Previously, the company expected adjusted earnings in the range of $7.47 to $7.57 per share on revenue growth of 6.5 to 7.0 percent from last year on a reported basis.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $7.50 per share on revenue growth of 6.6 percent to $7.40 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Zimmer Biomet Trims FY24 Revenue Growth Outlook; To Acquire OrthoGrid Systems - Update
Zimmer Biomet Receives FDA's 510(k) Clearance For ROSA Shoulder System
Zimmer Biomet Guides FY24 Above Estimates - Update
Zimmer Biomet Promotes COO Ivan Tornos To Succeed Bryan Hanson As President And CEO
Zimmer Biomet Boosts FY23 Outlook - Update
Zimmer Biomet Receives FDA 510(k) Clearance For Identity Shoulder System
Target Q2 Down, Yet Beats Street, Backs FY25 View, Names Michael Fiddelke CEO; Shares Hit
